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ABSTRACT: Glycosaminoglycans (GAGs) play critical roles in diverse processes ranging from viral infection to neuroregeneration. Their 
regiospecific sulfation patterns, which are generated by sulfotransferases, are key structural determinants that underlie their biological activity. 
Small-molecule modulators of these sulfotransferases could serve as powerful tools for understanding the physiological functions of GAGs, as 
well as potential therapeutic leads for human diseases. Here, we report the development of the first cell-permeable, small-molecule inhibitor 
selective for GAG sulfotransferases, which was obtained using a high-throughput screen targeted against Chst15, the sulfotransferase respon-
sible for biosynthesis of chondroitin sulfate-E (CS-E). We demonstrate that the molecule specifically inhibits GAG sulfotransferases in vitro, 
decreases CS-E and overall sulfation levels on cell-surface and secreted chondroitin sulfate proteoglycans (CSPGs), and reverses CSPG-
mediated inhibition of axonal growth. These studies pave the way toward a new set of pharmacological tools for interrogating GAG sulfation-
dependent processes and may represent a novel therapeutic approach for neuroregeneration. 
INTRODUCTION 
Glycosaminoglycans (GAGs) play important roles in a myriad of 
cellular processes, including viral invasion,1-4 cancer metastasis,1,5-7 
development,1,3,8,9 and spinal cord injury.7,9-12 Their diverse biologi-
cal activities are believed to stem from their complex structures, 
which allow them to interact with a wide range of proteins.1,3,7,13,14 
GAGs are long, linear polysaccharides that display various patterns 
of sulfation. For example, chondroitin sulfate (CS) GAGs are as-
sembled from glucuronic acid (GlcA) and N-acetylgalactosamine 
(GalNAc) disaccharide units that contain at least four distinct sul-
fation motifs: CS-A, CS-C, CS-D, and CS-E.7,12 Numerous studies 
suggest that specific sulfation motifs can serve as key structural 
elements for protein recognition and the regulation of downstream 
signaling.1,7,14-17  
The sulfation patterns of GAGs are controlled by a family of sul-
fotransferases.18-21 Two major classes of the enzymes, the cytosolic 
and membrane-associated sulfotransferases, catalyze the transfer of 
a sulfuryl group from the donor 3’-phosphoadenosine-5’-
phosphosulfate (PAPS) to a variety of amine- and hydroxyl-
containing substrates.18,21 The cytosolic sulfotransferases act on 
small-molecule substrates such as xenobiotics. With only one ex-
ception, the sulfotransferases responsible for modifying GAG poly-
saccharides are type II transmembrane proteins that reside in the 
Golgi apparatus. All sulfotransferases have a structurally conserved 
PAPS-binding site, but distinct acceptor binding sites.18,21 Although 
numerous cytosolic sulfotransferases have been crystallized, only 
limited structural and functional information on GAG sulfotrans-
ferases is available, which has hindered efforts to design tools to 
target these enzymes. Indeed, there are no cell-permeable, small-
molecule inhibitors of any GAG sulfotransferases. Prior work has 
focused on peptide- or carbohydrate-based inhibitors22-24 such as 
sulfated or iminosugars that displayed limited cell permeability due 
to the presence of charged groups.22,23 Thus, despite long-standing 
interest in inhibiting GAG sulfotransferases,25,26 it was unclear 
whether small molecules could be developed to selectively target 
this important class of enzymes in a cellular context.  
GAG sulfotransferase inhibitors would provide valuable tools for 
manipulating GAG sulfation patterns and for understanding their 
roles in biology and disease. The induced expression of specific 
sulfation motifs is associated with human diseases, including cer-
tain cancers,27,28 Alzheimer’s disease,29 osteoarthritis,30,31 malaria,32,33 
herpes,2 and macular corneal dystrophy,34 but surprisingly, pharma-
cological tools for manipulating GAG sulfation have been lacking. 
Cellular sulfation levels can be modulated genetically or by using 
sodium chlorate, which inhibits PAPS synthetase.19,20,35-37 However, 
genetic approaches lack the ease and reversibility of small-molecule 
inhibitors. Sodium chlorate requires millimolar concentrations and 
globally affects all sulfotransferases, disrupting the sulfation of 
hormones, bioamines, xenobiotics, proteins, and other glycans, and 
inducing off-target effects such as suppression of cell proliferation 
and replication.35-38 Moreover, the toxicity of sodium chlorate due 
to oxidation of hemoglobin and other metalloproteins limits its 
biological applications and therapeutic potential.39  
Here, we sought to develop selective inhibitors for GAG  
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 Figure 1. Identification of two lead inhibitor scaffolds. (A) Enzyme-
coupled fluorescence assay for the high-throughput screening of small-
molecule inhibitors of Chst15. Chst15 activity was monitored by cou-
pling to Sult1c1, which converted MUS to fluorescent MU.  (B) Dose-
dependent inhibition of Chst15 by compounds 5 and 19 using a [35S]-
labeling assay. 
 
sulfotransferases. As a starting point, we targeted Chst15, the 
chondroitin sulfotransferase responsible for sulfating the 6-O-
position of N-acetylgalactosamine in CS-A to generate CS-E (Fig-
ure 1A).19,20,40 Previously our laboratory identified the CS-E motif 
as an important structural determinant in chondroitin sulfate pro-
teoglycans (CSPGs) that inhibits axon regeneration after central 
nervous system (CNS) injury.17 Blocking the CS-E motif using a 
monoclonal antibody specific for CS-E promoted optic nerve re-
generation in vivo.17 As such, Chst15 may represent a novel target 
for neuronal repair after spinal cord injury, stroke, or other injuries.  
In this report, we describe the first cell-permeable, small-
molecule inhibitors of Chst15 and other GAG sulfotransferases. 
Using a fluorescence-based, high-throughput screen (HTS), we 
identified two promising scaffolds that upon structure-activity rela-
tionship (SAR) optimization led to molecules with improved po-
tency in biochemical and cellular assays. Kinetic analyses revealed a 
reversible-covalent mechanism of inhibition, along with good selec-
tivity toward GAG sulfotransferases compared to cytosolic sul-
fotransferases. Notably, the most potent inhibitor decreased CS-E 
sulfation levels on CSPGs and reversed the inhibitory activity of 
CSPGs on axonal growth. These studies open the door to a new set 
of chemical genetic tools for manipulating and understanding 
GAG-mediated events, as well as a novel potential therapeutic 
strategy for neuroregeneration.   
 
RESULTS AND DISCUSSION 
 
 
To discover molecules that inhibit Chst15, we developed a fluo-
rescence-based assay in which Chst15 activity was coupled to the 
enzyme Sult1c1 (Figure 1A). Sult1c1 converts 3’-
phosphoadenosine-5’-phosphate (PAP) to PAPS by using 4-
methylumbelliferyl sulfate (MUS) as the sulfate donor, resulting in 
liberation of fluorescent 4-methylumbelliferone (MU).41,42 We 
optimized and validated the assay in 96-well plates to obtain a Z-
factor value suitable for high-throughput screening (0.62; Figure 
S1). The assay was then miniaturized to a 1536-well plate format, 
and a diversity set of 70,000 compounds was screened at 12.5 μM 
for its ability to inhibit human Chst15. The hits obtained were 
counter-screened against Sult1c1, resulting in nineteen compounds 
(renumbered 1-19) that inhibited Chst15 with little or no Sult1c1 
inhibition (Figure S2A). To validate these compounds further, we 
used a direct, sensitive assay that monitored [35S]-incorporation 
from [35S]-PAPS into CS-A (Figure S2B). The top compounds, 5 
and 19, exhibited significant dose-dependent inhibition of Chst15 
with IC50 values of 23 μM and 39 μM, respectively (Figure 1B).  
To further evaluate 5, we re-tested its activity and that of several 
commercially available analogs using the [35S]-labeling assay (Fig-
ure S3). Although 5 effectively inhibited Chst15, none of the ana-
logs showed improved inhibition, and 5 also unexpectedly showed 
cross-reactivity toward Sult1c1 when re-evaluated in the counter-
screen (12.5 μM, Figure S4). We therefore focused our attention 
on 19. Thirty-one analogs of 19 were synthesized or obtained 
commercially (Tables 1 and 2; Figure S5). To facilitate diversifica-
tion of the molecule, we devised two synthetic routes that allowed 
for modification of the anilide or vinylbenzene moieties (Scheme 
1). Initial formation of the α,β-unsaturated acid followed by an 
N,N’-diisopropylcarbodiimide (DIC)-promoted amide bond cou-
pling enabled functional groups around the anilide to be altered. 
Alternatively, synthesis of the cyanoacetamide in two steps permit-
ted incorporation of different vinylbenzene substituents by a piper-
idinium acetate-catalyzed Knoevenagel condensation. These routes 
enabled the installation of a wide range of functionalities from a 
 
Scheme 1. Synthesis of Analogs of 19a 
 
aReagents and conditions: (a) ethyl cyanoacetate, piperidine, AcOH, 
PhMe (91%); (b) NaOH, THF (77%); (c) Ar-NH2, DIC, THF (17-
56%); (d) cyanoacetic acid, DIC, THF (45%); (e) Ar-CHO, piperi-
dine, AcOH, PhMe (52-93%). See Table 1, Table 2, and Figure S5 for 
specific structures. 
a, b c
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 Table 1. Relative Inhibition of Chst15 by Anilide Ana-
logsa  
aRelative inhibition values were determined from three independent 
measurements using 25 μM of inhibitor and normalized to the inhibi-
tion by compound 19. 
 
Table 2. Relative Inhibition of Chst15 by Vinylbenzene-
Analogsa 
aSee footnote from Table 1. 
 
large pool of commercially available anilines and benzaldehydes. 
We compared the inhibitory activities of the analogs using the 
[35S]-labeling assay. Removal of either aromatic ring on 19 (21, 23, 
46, Scheme 1 and Figure S5) abolished activity, and changing the 
anilide ring from di- to mono-substitution (25-33) greatly reduced 
its potency (Table 1 and Figure S5). Altering the position of mono-
substitution (31, 32) did not change this trend, nor did substitu-
tion with larger groups such as tert-butyl (30), phenyl (33), or 
fused-phenyl substituents (48, Figure S5). The importance of di-
substitution was highlighted further upon analysis of various di-
chloro-substituted analogs (34-36), which had comparable or 
greater potency than the original compound 19. In particular, com-
pound 34 showed 35% greater potency when compared to 19 in 
the [35S]-labeling assay. 
We next explored the importance of the vinylbenzene substitu-
ents by synthesizing analogs derived from 34. Removal of any of 
the three substituents on the vinylbenzene ring (37, 41, 44) greatly 
attenuated the inhibitory potency of the compound (Table 2). 
Replacement of the bromo substituent with other halogens (38- 
40) decreased the activity by up to 2.5-fold, suggesting that the 
stereoelectronic properties of the bromo group are well suited for 
binding the enzyme. By comparison, modifications to the methoxy 
group were more tolerated. For example, replacement of the meth-
oxy with a bromo group (42) led to no significant change in poten-
cy, while replacement with an ethoxy group (43) enhanced poten-
cy by 26% as compared to 19. However, neither of these analogs 
exhibited improved potency when compared to 34. Meanwhile, 
modification of the phenol group to aniline (45) or indazole (49, 
Figure S5) decreased the potency by 3-fold and 26-fold, respective-
ly. Methylation of the phenol functionality also drastically lowered 
the inhibitory potency for compounds with common scaffolds (e.g. 
35 vs. 47, Table 1 and Figure S5). Thus, the hydrogen bonding and 
electronic properties of the phenolic hydroxyl group are important 
for Chst15 inhibition.  
We hypothesized that the α,β-unsaturated cyanoacrylamide moi-
ety might serve as an electrophile for nucleophilic amino acid side 
chains. Indeed, cyanoacrylamide compounds have been reported to 
inhibit kinases via a reversible covalent mechanism by reacting with 
noncatalytic cysteine residues.43,44 Rotating frame nuclear Overhau-
ser effect spectroscopy (ROESY) data suggested that the E-isomer 
is generated in 34 after the Knoevengel condensation (Figure S6). 
Specifically, correlations between the amide and alkene protons of 
34 were detected, which is only possible in the E-configuration. 
Reduction of this E-olefin using Pd/C abolished the dose-
dependent effects of 34 (50, Figure S5).  
To investigate the electrophilic potential of 34, we incubated it 
with a surrogate nucleophile, β-mercaptoethanol (BME, Figure 
S7A). Consistent with the formation of a covalent thioether ad-
duct,43  we observed a decrease in the UV-visible absorption band 
corresponding to the cyanoacrylamide moiety (λmax = 378 nm; 
Figure S7B). Upon ten-fold dilution of the sample treated with 
BME into phosphate buffered saline (PBS), the absorbance was 
restored as compared to dilution into PBS containing BME, sug-
gesting that formation of the adduct was reversible (Figure S7C). 
Further evidence for a reversible covalent adduct was obtained by 
1H NMR spectroscopy (Figure S7D). Incubation of 34 with BME 
led to partial loss of the olefinic proton ( = 7.83 ppm) and appear-
ance of an aliphatic β-proton ( = 4.49 ppm). Peak integrations 
indicated that ~57% of the population had formed the thioether 
adduct, and this population was reduced to ~37% upon two-fold 
dilution into PBS.  
We also examined whether 34 inhibits Chst15 through a reversi-
ble covalent mechanism by pre-incubating the inhibitor with 
Chst15 for various lengths of time. Longer pre-incubation times 
lead to greater inhibition of the enzyme, consistent with a covalent 
mechanism of action (Figure S8A). However, unlike the inhibition 
typically observed with irreversible covalent inhibitors, the activity 
of Chst15 was rapidly restored in ten-fold dilution experiments  
Compound R1 R2 R3 R4 Relative Inhibition
19 H F Cl H 1.00 ± 0.01
25 H F H H 0.19 ± 0.00
26 H Cl H H 0.30 ± 0.04
27 H Br H H 0.10 ± 0.00
28 H Me H H 0.08 ± 0.00
29 H CF3 H H 0.10 ± 0.00
30 H tBu H H 0.35 ± 0.05
31 H H H Cl 0.57 ± 0.02
32 H H H F 0.37 ± 0.00
33 H H Ph H 0.07 ± 0.01 
34 H Cl H Cl 1.35 ± 0.12
35 Cl H Cl H 0.98 ± 0.10
36 Cl H H Cl 1.21 ± 0.09
Compound R5 R6 R7 Relative Inhibition
34 OMe OH Br 1.35 ± 0.12
37 OMe OH H 0.13 ± 0.00
38 OMe OH F 0.40 ± 0.03
39 OMe OH Cl 0.49 ± 0.01
40 OMe OH I 0.88 ± 0.02
41 H OH Br 0.32 ± 0.00
42 Br OH Br 0.97 ± 0.10
43 OEt OH Br 1.26 ± 0.16
44 OMe H Br 0.00 ± 0.00
45 OMe NH2 Br 0.32 ± 0.01
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Figure 2. Kinetic analysis and specificity of compound 34. Pseudo 
first-order studies using the enzyme-coupled fluorescence assay 
revealed a competitive and mixed mode of inhibition for the sub-
strates (A) PAPS and (B) CS-A, respectively. (C) Compound 34 
displayed 8- to 18-fold greater specificity for GAG sulfotransferases 
compared to cytosolic sulfotransferases. 
 
even at high concentrations of 34 (up to 100 μM). These observa-
tions suggest dissociation of the enzyme-inhibitor complex, thus 
supporting its reversibility (Figure S8B).  
To study the mechanism further, we performed pseudo first-
order kinetic analyses with compound 34. When the CS-A sub-
strate concentration was varied under pseudo first-order conditions 
with respect to PAPS, we obtained Ki and Ki’ values of 1.43 μM and 
2.45 μM, respectively, and observed a shift in both Vmax and Km 
indicative of a mixed mode of inhibition (Figure 2A, Table S1, Fig-
ure S10). However, when the PAPS concentration was varied un-
der pseudo first-order conditions with respect to the CS-A acceptor 
substrate, we observed a competitive mode of inhibition with a Ki 
value of 0.77 μM (Figure 2B, Table S1, Figure S10). Taken togeth-
er, these results suggest that inhibitor 34 competitively interacts 
with the PAPS binding site and also likely engages part of the ac-
ceptor binding site.  
Due to its electrophilic mechanism of action, 34 could potential-
ly react with numerous proteins that contain reactive cysteine resi-
dues. Cravatt and co-workers have previously identified reactive 
cysteine-containing proteins using the iodoacetamide-alkyne probe 
51 (Figure S9A), which alkylates reactive cysteine residues and 
allows for visualization of the proteins following copper-catalyzed 
azide-alkyne cycloaddition (CuAAC).45 Among the most highly 
reactive proteins were thioredoxin, protein arginine methyltrans-
ferase 1 (PRMT1), aldehyde dehydrogenase 1A (ALDH1A), ace-
tyl-CoA acetyltransferase 1 (ACAT1), and glutathione S-
transferase omega 1 (GTSO1). We incubated each of these pro-
teins with iodoacetamide probe 51 (25 μM) in the presence or 
absence of 34 (10 and 25 μM) for 2 h at room temperature, and 
then reacted them with 5-carboxytetramethylrhodamine-azide 
(azido-TAMRA). Importantly, no decrease in the labeling of any of 
the proteins by 51 was observed, as visualized by in-gel fluores-
cence (Figure S9B). These data indicate that compound 34 does 
not react non-specifically with some of the most reactive cysteine 
residues in the proteome. As further evidence, we incubated Neu7 
astrocytes in the presence or absence of 34 (25 μM) for 24 h, fol-
lowed by treatment with 51 for 1 h.  Again, the labeling of proteins 
by iodoacetamide probe 51 was unchanged upon treatment with 
34 (Figure S9B). Together, our studies provide strong evidence 
that inhibitor 34 is selective for sulfotransferases over the myriad of 
reactive cysteine-containing proteins in the proteome. 
We next investigated the specificity of 34 against a series of cyto-
solic and GAG sulfotransferases. Importantly, we observed a clear 
dichotomy in the ability of 34 to inhibit GAG sulfotransferases 
compared to cytosolic sulfotransferases (Figure 2C). While 34 
inhibited Chst15 and other closely related GAG sulfotransferases 
such as the chondroitin 4-O-sulfotransferase Chst11, the chon-
droitin 2-O-sulfotransferase Ust, and the heparan 3-O-
sulfotransferase Hs3st1 (IC50 values 2.0-2.5 μM), its activity against 
the cytosolic sulfotransferases Sult1e1, Sult2b1a, and Sult2b1b, 
which modify steroidal substrates, was significantly lower (IC50 
values 19-42 μM). Moreover, 34 showed no activity against the 
cytosolic sulfotransferase Sult1c1 used in the enzyme-coupled assay 
at the concentrations tested (3-100 μM). Inhibition of other GAG 
sulfotransferases by 34 is consistent with the high sequence ho-
mology (25-81%) shared by GAG sulfotransferases40,46,47 and our 
observations that 34 engages the PAPS binding pocket.  
Figure 3. Treatment of Neu7 astrocytes with 34 reduces expression of 
CS-E on cell-surface and secreted CSPGs. (A) Representative images 
of Neu7 astrocytes treated with 34 or chlorate and co-stained with a 
CS-E-specific antibody (green) and the nuclear stain DAPI (blue). (B) 
Quantification of the average fluorescence from anti-CS-E im-
munostaining under each condition. Values represent the mean ± 
S.E.M. from three experiments. n = 20-100 cells per experiment. (C) 
CS-A, CS-E, and uCS disaccharide composition of secreted CSPGs 
from Neu7 astrocytes treated with 34 or sodium chlorate. n = 3. *P < 
0.05, **P < 0.01, ***P < 0.001, n.s. = not significant. For B, P values are 
calculated relative to the vehicle control. (Scale bar: 100 μm.) 
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Figure 4. Treatment of Neu7 astrocytes with 34 attenuates CSPG-
mediated inhibition of sensory neurite outgrowth and repulsion. 
(A) Representative images and quantification of DRG neurite out-
growth recovery for CSPGs purified from treated astrocytes relative 
to CSPGs purified from untreated astrocytes. Data represent the 
mean ± S.E.M. from three experiments. n = 20-80 cells per experi-
ment. (B) Representative images and quantification of neurite 
crossing for DRG neurons grown in the presence of a boundary 
(shown in red) of CSPGs purified from treated or untreated astro-
cytes. Data represent the mean ± S.E.M. from five experiments. n = 
20-40 cells per experiment. *P < 0.05, **P < 0.01, n.s. = not signifi-
cant. For A, P values are calculated relative to growth on CSPGs 
from untreated astrocytes. (Scale bars: 50 μm.) 
 
The ability to inhibit GAG sulfation after CNS injury could have 
important implications for neural regeneration. After CNS injury, 
reactive astrocytes enter the site of injury and secrete CSPGs as a 
means to prevent further damage.9-11 Previous studies in our labora-
tory have established that the CS-E sulfation motif is upregulated 
on these CSPGs and inhibits the growth of sensory axons.17 Thus, 
we first examined whether 34 could modulate CS-E expression 
levels on CSPG-secreting Neu7 astrocytes.48 Indeed, astrocytes 
treated with 10 μM or 25 μM of 34 showed a significant, dose-
dependent decrease in cell-surface CS-E expression, as indicated by 
immunostaining with a CS-E-specific antibody49 (Figure 3A and 
3B). Notably, no cytotoxicity was observable at the concentrations 
tested when analyzed by the trypan blue exclusion assay (up to 25 
μM). By comparison, sodium chlorate did not reduce CS-E levels 
to as large an extent, even at doses as high as 25 mM. Similar results 
were obtained using NIH3T3 fibroblasts, where significant loss of 
CS-E expression was observed upon treatment with 34, and 34 had 
superior potency compared to sodium chlorate (Figure S11).  
     To characterize the effects of 34 on secreted CSPGs, we purified 
the CSPGs from Neu7-conditioned media, digested them with 
chondroitinase ABC (ChABC), and analyzed their disaccharide 
composition by reverse-phase ion-pair high-performance liquid 
chromatography (RPIP-HPLC). CSPGs secreted from Neu7 as-
trocytes treated with 25 μM of 34 displayed a 62.9 ± 17.0% increase 
in unsulfated chondroitin (uCS) content compared to CSPGs 
secreted from untreated astrocytes, indicating a decrease in overall 
sulfation (Figure 3C, Table S2). This overall decrease was accom-
panied by a specific 67.8 ± 10.9% reduction in the CS-E sulfation 
motif on secreted CSPGs. Although other CS sulfation motifs were 
also affected, the CS-E motif was reduced to the largest extent 
(Figure S12). By comparison, CSPGs secreted from sodiumchlo-
rate-treated cells also displayed lower sulfation compared to un-
treated cells, albeit to a lesser degree and only in the presence of 
high concentrations of sodium chlorate (39.7 ± 15.6% increase in 
uCS; 31.6 ± 10.9 % decrease in CS-E).  
Having shown that 34 can effectively inhibit CS-E sulfation lev-
els on both surface-expressed and secreted CSPGs, we next exam-
ined whether this mode of inhibition could be exploited to stimu 
late axonal growth. Sensory dorsal root ganglion neurons (DRGs) 
adjacent to the rat spinal cord were grown on a substratum coated 
with the CSPGs secreted from Neu7 astrocytes treated with or 
without 34. The effects of the CSPGs on neurite outgrowth were 
determined by immunostaining for the neuronal-specific marker, 
βIII-tubulin, and quantifying the average neurite length. To our 
delight, we observed a significant, dose-dependent promotion of 
neurite outgrowth (30.7 ± 2.5% at 25 μM of 34) when DRGs were 
grown on CSPGs secreted from treated astrocytes compared to 
untreated astrocytes (Figure 4A). The observed effects could stem 
from direct inhibition of Chst15 and/or indirect effects on other 
GAG sulfotransferases such as Chst11, which creates the substrate 
for Chst15. These results highlight not only the ability of 34 to 
block known functions of CSPGs but also the potential value of 
pan-specific GAG sulfotransferase inhibitors. In many cases, the 
relative contributions of various sulfation motifs and GAG sub-
classes have not been fully investigated; thus, pan-specific inhibi-
tors may be ideal and enable validation of therapeutic hypotheses. 
CNS injury induces tissue damage and leads to formation of a 
glial scar, which consists predominantly of reactive astrocytes and 
CSPGs.9-11 The glial scar serves as a major barrier to axon regenera-
tion.  We used an in vitro boundary assay to simulate the glial scar 
and assess the ability of 34 to reverse the inhibitory activity of 
CSPGs. In this assay, purified CSPGs from Neu7 astrocytes treated 
with or without 34 were mixed with Texas Red dye and spotted 
onto glass coverslips. DRG neurons were plated onto the co-
verslips, and the percentage of neurites that crossed the CSPG 
boundary was quantified. Whereas DRG neurites were strongly 
repelled by CSPGs from untreated astrocytes, they crossed more 
freely into boundaries of CSPGs from astrocytes treated with 34 
(Figure 4B).  Thus, compound 34 rendered CSPGs more permis-
sive to axonal growth, demonstrating its ability to modulate sul-
fation-dependent cellular processes. 
 Finally, we evaluated the potential to use inhibitor 34 in vivo by 
profiling its absorption, distribution, metabolism, and elimination 
(ADME) properties. 34 showed good stability in human, mouse 
and rat liver microsomes based on intrinsic clearance (Table S3). 
The in vivo pharmacokinetic (PK) properties of 34 were also eval-
uated directly in rats. After intravenous injection of compound 34 
at a dose of 3.0 mg/kg, the compound had a moderate clearance of 
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 21 mL/min/kg, moderate volume of distribution of 0.97 L/kg, and 
short terminal half-life of 1.6 h (Table S4). These data suggest that 
direct application of the compound, as opposed to intravenous 
injection, may be more efficacious for future use in vivo. Taken 
together, our studies demonstrate that the sulfotransferase inhibi-
tor 34 can diminish the inhibitory effects of CSPGs, and they high-
light its promise to be used for the stimulation of neuronal repair. 
 
CONCLUSION 
GAG sulfotransferase inhibitors have the potential to be power-
ful pharmacological tools for elucidating the diverse physiological 
functions of GAGs and serve as potential therapeutic leads for spi-
nal cord regeneration and human diseases. We report here the dis-
covery of the first cell-permeable, small-molecule inhibitor selective 
for GAG sulfotransferases. Inhibitor 34 was derived from a high-
throughput screen targeted against the CS-E sulfotransferase 
Chst15 and potently inhibited the sulfation of surface-expressed 
and secreted CSPGs. Importantly, by decreasing sulfation levels on 
CSPGs, compound 34 reversed the growth inhibitory effects of 
CSPGs on sensory axons. These studies demonstrate, for the first 
time, the ability to modulate a class of enzymes for which, despite 
high interest, no cell-permeable, small-molecule inhibitors exist. 
Furthermore, they highlight the promise of using a sulfotransferase 
inhibitor-based strategy, and potentially 34 or its derivatives, for 
the stimulation of neuronal growth after injury, stroke, or neuro-
degenerative disease. Finally, compound 34 provides a lead scaffold 
that may be further developed to target individual sulfotransferases 
with high specificity. Owing to the major lack of tools for studying 
sulfation, we envision that chemically-tuned small molecules capa-
ble of modulating specific GAG sulfation patterns will find exten-
sive use as tools in manipulating and understanding GAG-
dependent physiological and pathological processes. 
METHODS 
Detailed experimental procedures are provided in the Supporting In-
formation. 
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